1. ANTI‐INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY‐ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R‐CHOP IMMUNOCHEMOTHERAPY. (June 2017) Authors: Murawski, N.; Amam, J.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A.; Neubauer, A.; Held, G.; Truemper, L.; Dreyling, M.; Kanz, L.; Hallek, M.; Schmitz, N.; Heintges, T.; Koelbel, C.; Poeschel, V.; Pfreundschuh, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). (October 2017) Authors: Modest, D.P.; Ricard, I.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C.B.; Holch, J.W.; von Einem, J.C.; Held, S.; Heinemann, V. Journal: European journal of cancer Issue: Volume 84(2017) Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. RADIOTHERAPY TO BULKY DISEASE PET‐NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL. (June 2017) Authors: Pfreundschuh, M.; Christofyllakis, K.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A.; Neubauer, A.; Held, G.; Truemper, L.; Dreyling, M.; Kanz, L.; Hallek, M.; Schmitz, N.; Heintges, T.; Kölbel, C.; Buecker, A.; Ruebe, C.; Hellwig, D.; Berdel, C.; Poeschel, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). (January 2019) Authors: Holch, J.W.; Ricard, I.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D.P.; Westphalen, C.B.; von Einem, J.C.; Michl, M.; Heinemann, V. Journal: European journal of cancer Issue: Volume 106(2019) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗